EAST-ASIA PHARMACEUTICAL released its performance for the first three quarters, with a net loss attributable to the parent company of 72.41 million yuan
According to the Zhitong Finance APP, EAST-ASIA PHARMACEUTICAL disclosed its third-quarter report for 2025. The company achieved a revenue of 596 million yuan in the first three quarters, a year-on-year decrease of 38.08%; the net profit attributable to shareholders was a loss of 72.41 million yuan; the net profit excluding non-recurring items was a loss of 81.98 million yuan; the basic earnings per share were -0.63 yuan
According to the Zhitong Finance APP, EAST-ASIA PHARMACEUTICAL (605177.SH) disclosed its third-quarter report for 2025. The company achieved a revenue of 596 million yuan in the first three quarters, a year-on-year decrease of 38.08%; the net profit attributable to shareholders was a loss of 72.41 million yuan; the net profit excluding non-recurring gains and losses was a loss of 81.98 million yuan; basic earnings per share were -0.63 yuan
